Marina Biotech, Inc. (OTCMKTS:MRNA) Files An 8-K Other Events
Item 8.01 Other Events.
On May 5, 2017, Marina Biotech, Inc. (the Company) filed with the
Securities and Exchange Commission (the SEC) a Post-Effective
Amendment No. 4 to Form S-3 on Form S-1 with respect to
registration statement nos. 333-168447 and 333-175769 (the
Post-Effective Amendment) to maintain the registration of the
issuance of shares of the common stock of the Company (Common
Stock) to the holders of certain warrants to purchase shares of
Common Stock that were issued in connection with the underwritten
public offerings of common stock and warrants that the Company
conducted in February 2011 (the February 2011 Offering) and May
2011 (the May 2011 Offering).
The Post-Effective Amendment was declared effective by the SEC on
May 15, 2017. Since that time, warrants to purchase up to 609,440
shares of Common Stock that were issued in the May 2011 Offering
have been exercised, at an exercise price of $0.28, resulting in
gross proceeds to the Company of approximately $170,000. All of
the warrants issued in the May 2011 Offering expired by their
terms on May 22, 2017.
Following the expiration of all of the warrants issued in the May
2011 Offering, the only warrants the exercise of which are
covered by the Post-Effective Amendment are warrants to purchase
up to 111,308 shares of Common Stock having an exercise price of
$8.00 per share that were issued in the February 2011 Offering.
About Marina Biotech, Inc. (OTCMKTS:MRNA)
Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2). Marina Biotech, Inc. (OTCMKTS:MRNA) Recent Trading Information
Marina Biotech, Inc. (OTCMKTS:MRNA) closed its last trading session 00.000 at 0.297 with 7,251 shares trading hands.